Core Viewpoint - Yonghe Intelligent Control (002795.SZ) expects a loss of 145 million to 250 million yuan in 2025, representing an increase of 15.90% to 51.22% compared to the same period last year [1] Financial Performance - The company anticipates a non-recurring loss of 132 million to 238 million yuan for the reporting period [1] - The primary reasons for the losses include a decrease in revenue from the valve and pipe fittings business and a decline in income from other business segments [1] Asset Valuation - The company is facing high depreciation and amortization costs, which are contributing to the overall financial strain [1] - Preliminary assessments by the auditing agency indicate potential impairment of long-term assets, with the final determination pending further audits [1]

Core Viewpoint - The aggressive cross-industry expansion of Yonghe Zhikong into the medical and photovoltaic sectors has resulted in significant financial losses and asset disposals, culminating in a drastic drop in asset values to as low as 1 yuan, reflecting the harsh realities of failed diversification efforts [1][5]. Group 1: Cross-Industry Expansion - Yonghe Zhikong began its cross-industry journey in 2019 under the new control of Cao Delin, aggressively acquiring multiple tumor hospitals, with total expenditures exceeding 240 million yuan, despite these hospitals already being in a loss-making state at the time of acquisition [1][2]. - In 2022, the company attempted to enter the photovoltaic sector by increasing its stake in Taixing Pule, aiming to capitalize on the renewable energy trend, but this move did not yield the expected growth [2]. Group 2: Financial Losses - From 2022 to 2024, Yonghe Zhikong reported net losses of 26.19 million yuan, 156 million yuan, and 297 million yuan respectively, accumulating a total loss of 479 million yuan over three years [3]. - By the third quarter of 2025, the company continued to experience losses, with a net profit loss of 60.46 million yuan, indicating no signs of recovery [3]. - The company's debt situation worsened, with the debt-to-asset ratio soaring from 12.8% at the time of its IPO in 2016 to 73.24% by the end of the third quarter of 2025 [3]. Group 3: Control and Strategic Challenges - Cao Delin's attempts to transfer control of the company have failed three times since 2022, reflecting a lack of strategic direction and increasing operational challenges [4]. - The first attempt to transfer control to Huzhou Hecheng was terminated within a month, and subsequent attempts with other parties also failed, highlighting the difficulties in divesting from unprofitable assets [4]. - As of the 2025 semi-annual report, the company's main business revenue was predominantly from valve fittings, accounting for 89.41%, while contributions from medical services and photovoltaic segments were negligible [4].

Group 1 - The core viewpoint of the news is that Yonghe Intelligent Control Co., Ltd. has seen a stock price increase of 5.14%, reaching 6.55 CNY per share, with a trading volume of 1.23 billion CNY and a turnover rate of 4.46%, resulting in a total market capitalization of 28.93 billion CNY [1] - Yonghe Intelligent Control, established on August 28, 2003, and listed on April 28, 2016, operates primarily in the medical health industry and fluid control business, with revenue composition of 89.41% from valve and pipe fittings, 10.57% from medical services and other industries, and 0.02% from photovoltaic cells [1] Group 2 - From the perspective of major fund holdings, Yimin Fund has a significant position in Yonghe Intelligent Control, with its Yimin Core Growth Mixed Fund (560006) holding 49,500 shares, accounting for 1% of the fund's net value, ranking as the ninth largest holding [2] - The Yimin Core Growth Mixed Fund has a total scale of 24.98 million CNY, with a year-to-date return of 0.34% and a one-year return of 18.41%, ranking 5,299 out of 8,081 in its category [2] - The fund managers, Wang Yong and Guan Xu, have had varying performance, with Wang's best return during his tenure being 82.7% and Guan's best return being 35.84% [2]

Core Viewpoint - Yonghe Intelligent Control plans to publicly transfer 100% equity of its wholly-owned subsidiary Chengdu Mountain Water Hotel Co., Ltd. and the debt owed by Chengdu Yonghe Cheng Medical Technology Co., Ltd. to Chengdu Mountain Water, with a minimum initial listing price of 185 million yuan, aiming to optimize asset structure, improve cash flow, and enhance asset operation efficiency [1][2]. Group 1: Company Actions - The company is transferring the equity and debt to improve its asset structure and cash flow [1]. - This is not the first time the company has attempted to transfer Chengdu Mountain Water, as previous attempts were made in late 2024 to early 2025, but those transactions did not succeed [2]. - The company has been divesting from its underperforming assets in the tumor precision radiation treatment and photovoltaic sectors, including multiple hospitals and its stake in Puluo Technology [3]. Group 2: Financial Performance - As of July 2025, Chengdu Mountain Water had total assets of 108 million yuan, total liabilities of 126 million yuan, and negative equity of 1.77 million yuan [2]. - For the fiscal year 2024, Chengdu Mountain Water reported revenue of 19.51 million yuan and a net profit of 3.52 million yuan, with revenue and net profit for the first seven months of this year at 9.59 million yuan and 1.42 million yuan, respectively [2]. - Yonghe Intelligent Control reported a revenue of 582 million yuan for the first three quarters of this year, a year-on-year decrease of 7.25%, and a net loss of 60.46 million yuan [3].

Core Viewpoint - Yonghe Fluid Control Co., Ltd. (永和智控) is undergoing a significant change in control as its major shareholder, Cao Deli, transfers shares to Hangzhou Runfeng Intelligent Equipment Co., Ltd. for a total of approximately 320 million yuan, marking a shift in the company's leadership [1][2][5]. Share Transfer Details - Cao Deli signed a share transfer agreement on August 5, 2023, transferring 35.66 million shares (8% of total shares) at a price of 8.9736 yuan per share [1][5]. - Following the transfer, Hangzhou Runfeng will hold 8% of Yonghe's shares and 14.65% of voting rights, making it the new controlling shareholder [2][5]. - The share transfer price represents a premium of over 45% compared to Yonghe's closing price on August 6, 2023 [5]. Historical Context - This is not the first time Yonghe has sought a new controlling party; previous attempts included a planned transfer to Guangdong Pulu Green Energy Holdings in 2023, which ultimately fell through [6][7]. - The current transaction mirrors the previous one in terms of share price and quantity, indicating Cao Deli's persistent efforts to divest control [8]. Company Performance and Business Focus - Yonghe's main business includes plumbing valves and fittings, which account for 85% of its revenue, while its medical and photovoltaic businesses contribute 14.39% and 0.24%, respectively [9]. - Despite efforts to diversify into the medical and photovoltaic sectors, these ventures have not yielded significant profits, with medical revenue declining by 19.77% in 2024 and photovoltaic revenue being negligible [10][11]. Future Plans - Cao Deli has committed to facilitating the divestment of Yonghe's underperforming photovoltaic and medical assets by December 20, 2025, as part of the share transfer agreement [12].

Core Viewpoint - The article discusses the recent transfer of control at Yonghe Fluid Intelligent Control Co., Ltd. (Yonghe Zhikong), highlighting the sale of shares by its controlling shareholder, which has led to significant stock price fluctuations and reflects ongoing challenges in the company's strategic direction and performance [1][4][10]. Group 1: Share Transfer Details - Yonghe Zhikong's controlling shareholder, Cao Deli, signed a share transfer agreement with Hangzhou Runfeng, transferring 35.66 million shares (8% of total shares) at a price of 8.9736 yuan per share, totaling approximately 320 million yuan [1][4]. - Following the transfer, Hangzhou Runfeng will hold 8% of Yonghe Zhikong's shares and 14.65% of voting rights, making it the new controlling shareholder [1][4]. - The share transfer price represents a premium of over 45% compared to Yonghe Zhikong's closing price on August 6 [4]. Group 2: Historical Context and Previous Attempts - This is not the first time Yonghe Zhikong has sought a new controlling shareholder; previous attempts included a planned transfer to Guangdong Pule Green Energy Holdings, which ultimately fell through [4][5][6]. - Cao Deli's persistent efforts to divest control indicate a strategic shift, as he has been involved in multiple capital operations since taking control in November 2019 [4][6]. Group 3: Business Performance and Challenges - Yonghe Zhikong's main business segments include plumbing valves (85% of revenue), precision radiation therapy (14.39%), and photovoltaic (0.24%) [8]. - The company's foray into the medical field has not yielded significant results, with medical revenue dropping by 19.77% in 2024 compared to 2023, and a low gross margin of 7.96% [9]. - The photovoltaic segment has also underperformed, generating less than 20 million yuan in revenue in 2024, with a gross margin of -3020.96% [9][10]. Group 4: Future Outlook - Cao Deli has committed to facilitating the divestment of Yonghe Zhikong's underperforming photovoltaic and medical assets by December 20, 2025, as part of the control transfer agreement [10].

Core Viewpoint - The controlling shareholder of Yonghe Intelligent Control, Cao Deli, is transferring 35.66 million shares (8.00% of total shares) to Hangzhou Runfeng at a price of 8.9736 yuan per share, totaling 320 million yuan, which has led to a significant drop in the company's stock price following the announcement [1][2][3]. Group 1: Share Transfer and Control Change - Cao Deli and Yu Yaqin collectively controlled 46.73 million shares (10.49% of total shares) before the transfer [2]. - After the transfer, Hangzhou Runfeng will hold 8.00% of Yonghe Intelligent Control, and its actual controller, Sun Rongxiang, will have voting rights for 14.65% of the shares [3]. - The transfer does not trigger a mandatory takeover and is not classified as a related party transaction [3]. Group 2: Business Restructuring - Yonghe Intelligent Control plans to divest its medical and photovoltaic segments by December 20, 2023, as part of a restructuring effort [4]. - The company has reported consecutive annual losses from 2022 to 2024, with net profits of -26.70 million yuan, -156 million yuan, and -297 million yuan, indicating a worsening trend [4]. - The anticipated revenue for the first half of 2025 is projected between 330 million yuan and 380 million yuan, with expected losses of 30 million to 56 million yuan [4]. Group 3: Legal Issues - Yonghe Intelligent Control and its subsidiaries have been involved in multiple lawsuits, with a total amount of 64.83 million yuan in undisclosed litigation over the past 12 months, exceeding 10% of the company's latest audited net assets [5]. Group 4: Hangzhou Runfeng Background - Hangzhou Runfeng was established on July 22, 2023, with a registered capital of 20 million yuan, focusing on intelligent manufacturing equipment and robotics [6]. - The company has not yet engaged in any related business activities and plans to change its business scope within 10 working days [6]. - The controlling shareholder of Hangzhou Runfeng, Hangzhou Yuli Enterprise Management, was formed on July 14, 2023, and is linked to Sun Rongxiang, who holds a 35% stake in Zhejiang Yuli Electromechanical Technology [6][7].

Core Viewpoint - The stock price of Yonghe Intelligent Control (002795.SZ) dropped by 5.80% after the announcement of a share transfer agreement involving its controlling shareholder, Cao Deli, who plans to transfer 35.66 million shares (8.00% of total shares) to Hangzhou Runfeng at a price of 8.9736 yuan per share, totaling 320 million yuan [1][2]. Group 1: Share Transfer and Control Change - Cao Deli, the current controlling shareholder, will transfer his shares to Hangzhou Runfeng, which will result in Sun Rongxiang becoming the new controlling person of Yonghe Intelligent Control [2][3]. - After the share transfer, Hangzhou Runfeng will hold 8.00% of Yonghe Intelligent Control, and Sun Rongxiang will have voting rights corresponding to 14.65% of the shares [3]. - The share transfer does not trigger a mandatory tender offer and is not classified as a related party transaction, ensuring that the company's main business operations will not undergo significant changes [3]. Group 2: Business Operations and Financial Performance - Yonghe Intelligent Control's main business includes plumbing valves and tumor precision radiation therapy, with plans to divest from the photovoltaic and medical sectors by December 20, 2023 [4]. - The company has experienced declining performance over the past three years, with net losses of 26.70 million yuan in 2022, 156 million yuan in 2023, and an expected loss of 297 million yuan in 2024 [4]. - The revenue forecast for the first half of 2025 is between 330 million yuan and 380 million yuan, with anticipated net losses ranging from 30 million yuan to 56 million yuan due to decreased income from valve business and rising costs [4]. Group 3: Legal Issues and Company Background - Yonghe Intelligent Control and its subsidiaries are involved in multiple lawsuits, with a total amount of 64.83 million yuan in undisclosed litigation over the past twelve months, exceeding 10% of the company's latest audited net assets [5]. - Hangzhou Runfeng, established on July 22, 2023, has not yet commenced its intended business operations and will change its business scope shortly [6]. - The controlling shareholder of Hangzhou Runfeng, Zhejiang Yuli Electromechanical Technology Co., has been reported to be in a state of suspension since April 2023, raising concerns about the stability of the new controlling entity [7].

Group 1: IPO Guidance and Trends - In May, the China Securities Regulatory Commission (CSRC) disclosed 17 companies undergoing IPO guidance, bringing the total for 2025 to 123 companies [1] - The number of newly disclosed companies for guidance in May decreased compared to the previous months, with 32, 29, 23, and 22 companies in January to April respectively [1] - Notable companies disclosed in the last week of May include Huaxin New Materials, Tianhai Fluid Control, Chengdu Ultra-Pure Materials, and Chengfeng Technology [1] Group 2: Huaxin New Materials - Huaxin New Materials is the fourth globally and the first domestically to achieve mass production of high-performance polyimide (PI) films, filling a domestic gap and achieving import substitution [2] - The company was established in 2019 with a registered capital of 105 million yuan and has undergone five rounds of financing, attracting investments from notable institutions such as CRRC Capital and National Development Bank [3][4][5][6] - The company completed its IPO guidance registration with Guotai Junan Securities on May 28 [2] Group 3: Tianhai Fluid Control - Tianhai Fluid Control submitted its IPO guidance materials to the Anhui Securities Regulatory Bureau on May 21, with the application accepted on May 28 [7][8] - The company, established in 2012, has seen revenue growth from 2022 to 2024, with figures of 202 million yuan, 253 million yuan, and 287 million yuan respectively, showing year-on-year growth rates of 32.4%, 25.2%, and 13.3% [9] - Tianhai Fluid previously submitted an IPO application in December 2023 but was not accepted due to issues related to shareholding [9] Group 4: Chengdu Ultra-Pure Materials - Chengdu Ultra-Pure submitted its IPO guidance to the Sichuan Securities Regulatory Bureau on May 30, which was accepted [10] - Established in 2005, the company specializes in semiconductor etching devices and high-power laser devices, with a focus on advanced surface treatment processes [10] - The company has completed four rounds of financing, with significant participation from investors including BYD and TCL Venture Capital [11][12] Group 5: Chengfeng Technology - Chengfeng Technology submitted its IPO guidance materials on May 29, which were accepted by the Sichuan Regulatory Bureau [13] - The company, founded in 2009, specializes in the research, manufacturing, and sales of valves, with a significant portion of its revenue coming from domestic sales [14][15] - Despite a decline in net profit over the past two years, the company remains a key player in the valve market, ranking third in the sales of certain valve types [15]